Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
When utilizing hypofractionation for postmastectomy radiation, what is your strategy for boosting undissected nodes?
Related Questions
How do you approach breast hypofractionation RNI with the results of the Skagen Trial 1?
Would you offer partial breast irradiation for a patient who otherwise meets PBI guidelines but has a PTEN mutation?
For a patient who previously underwent PBI and then developed a second ipsilateral primary, would you offer repeat PBI?
How do you advise women to manage wound care for breast brachytherapy needle sites for long term cosmetic outcomes?
Would you consider whole breast re-irradiation in a patient with a second/recurrent breast cancer and prior history of breast radiation therapy many years ago, if the tumor characteristics are not amenable to partial breast re-irradiation?
Would you forgo lumpectomy cavity boost for grade 1 papillary carcinoma with associated grade 1 DCIS that has been resected with good margins?
Given the new ASCO guidelines on SNB in early stage breast cancer, how does the omission of SNB in patients aged 50-70 impact your adjuvant radiation recommendations?
How would you treat a schwannoma of the breast with a positive margin that is not amenable to re-excision?
How does a pathological CR to neoadjuvant chemotherapy influence your practice for the use of bolus with adjuvant PMRT patients without inflammatory breast cancer, but who would meet traditional risk factors for skin involvement?
Have the 10-year results from UK FAST-Forward presented at ESTRO 2025 impacted your practice with regard to patient selection?
